Answers are grounded in this paper and cite their sources.
KRAS is the most frequently mutated proto-oncogene in human cancers. Progression to advanced disease is frequently associated with allelic imbalance of the KRAS locus with gain of the mutant allele and loss of the wild-type allele through clonal and sub-clonal loss of heterozygosity (LOH). While a large body of literature has focused on the effects of allelic imbalance on oncogene addiction through gain of the mutant allele, the role of the wild-type KRAS proto-oncogene in malignant progression has not been fully elucidated. To capture this phenomenon, we developed a first-in-class somatic mosaic and lineage tracing genetically engineered mouse model (smGMLT) of pancreatic ductal adenocarcinoma allowing for real time in vivo tracing of Kras-LOH. Longitudinal characterization of the smGMLT demonstrated the presence of a strong evolutionary bottleneck towards the selective loss of the wild-type allele at metastatic sites. Cross species analysis leveraging research autopsies and surgical specimens revealed that KRAS-LOH is associated with metastatic dissemination and shorter overall survival. Transcriptomic analysis through single-cell RNA sequencing uncovered a conserved phenomenon whereby KRAS-LOH is paralleled by an immune evasive phenotype through loss of the tumor-cell interferon response and reduced CD8+ T cell infiltration. In line with this evidence, orthotopic transplants of isogenic tumor populations differing for the Kras allelic status demonstrated that only cancer cells with Kras-LOH are are able to form tumors in immune competent animals. Restoration of the wild-type allele abrogates tumorigenesis in KrasLOH transplants in immunocompetent through activation of the TBK1-IRF axis. Altogether, these studies demonstrate that the KRAS proto-oncogene is a functional tumor suppressor in pancreatic cancer exerting its function through interferon-mediated, cell-extrinsic modulation of the tumor immune microenvironment.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: